Acclivity Technologies, Inc. (ATI) is a discovery to preclinical health technologies company located in North Carolina. ATI’s lead drug candidate, ATI-0019, is a novel small molecule for a known atherosclerotic and ischemic disease target not previously known to be druggable by small molecules. Activation of this target reverses cardiovascular disease driver processes, including endothelial dysfunction, endothelial damage and loss of vasculature, inflammatory cell response, smooth muscle cell proliferation and migration, and platelet activation. We are testing and improving the pharmacological properties of ATI-0019, building a library of related compounds, and conducting in vitro and in vivo studies to establish the utility of ATI-0019 to treat our lead disease indication, peripheral artery disease, and its manifestations including intermittent claudication, critical limb ischemia, non-healing wounds, and diabetic foot. ATI-0019 and its derivatives will serve as the foundation for pipeline expansion to include other cardiovascular, inflammatory and ischemic disease indications, vasculitis, and type 2 diabetes. At ATI, we envision future technology development to include drug/device and diagnostic applications. Contact Us: info@acclivitytechnologies.com